UBS has reduced its target price for Lundbeck to DKK 45 from DKK 49 while maintaining a neutral stance on the company. Lundbeck A/S, a Danish pharmaceutical firm, specializes in developing treatments for brain disorders, including Alzheimer's, depression, and Parkinson's disease, with a diverse product portfolio.